Association between PRO 160/120 prescriptions and incidence of benign prostatic hyperplasia complications in Germany: a retrospective cohort study

References

• Irwin DE, Kopp ZS, Agatep B, et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132–1138.
   PubMed Web of Science ®Google Scholar
• Woodard TJ, Manigault KR, McBurrows NN, et al. Management of benign prostatic hyperplasia in older adults. Consult Pharm. 2016;31(8):412–424.
   PubMedGoogle Scholar
• Berges RR, Pientka L, Höfner K, et al. Male lower urinary tract symptoms and related health care seeking in Germany. Eur Urol. 2001;39(6):682–687.
   PubMed Web of Science ®Google Scholar
• Robertson C, Link CL, Onel E, et al. The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU Int. 2007;99(2):347–354.
   PubMed Web of Science ®Google Scholar
• Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology. 2019;65(5):458–464.
   PubMed Web of Science ®Google Scholar
• Ficarra V, Rossanese M, Zazzara M, et al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep. 2014;15(12):463.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. Definition of at-risk patients: baseline variables. BJU Int. 2006;97(2):7–11. discussion 21-2.
   PubMed Web of Science ®Google Scholar
• Benignes Prostatasyndrom A, Deutsche Gesellschaft Für Urologie EV, Berufsverband der Deutschen Urologen E. S2e Leitlinie – therapie des Benignen Prostatasyndroms (BPS). Norderstedt: Books on Demand GmbH; 2014. BoD –.
   Google Scholar
• Miernik A, Gratzke C. Current treatment for benign prostatic hyperplasia. Dtsch Arztebl Int. 2020;117(49):843–854.
   PubMed Web of Science ®Google Scholar
• Oelke M, Bachmann A, Descazeaud A, et al. European association of urology. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118–140.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract. 2008;62(10):1547–1559.
   PubMed Web of Science ®Google Scholar
• Wilt TJ, MacDonald R, Nelson D. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. J Urol. 2002;167(1):177–183. PMID: 11743300.
   PubMed Web of Science ®Google Scholar
• Sebastianelli A, Spatafora P, Morselli S, et al. Tadalafil alone or in combination with tamsulosin for the management for LUTS/BPH and ED. Curr Urol Rep. 2020;21(12):56.
   PubMed Web of Science ®Google Scholar
• Bschleipfer T, Burkart M. Einfluss medikamentöser BPS-Therapie auf die sexuelle Funktion [Influence of medical BPS treatment on sexual function]. Urologe A. 2018;57(12):1464–1471.
   PubMedGoogle Scholar
• Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther. 2007;29(1):17–25.
   PubMed Web of Science ®Google Scholar
• Keating GM. Dutasteride/tamsulosin: in benign prostatic hyperplasia. Drugs Aging. 2012;29(5):405–419.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Cui Y, Wu J, et al. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. BMC Urol. 2019;19(1):17.
   PubMed Web of Science ®Google Scholar
• Koch E. Extracts from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tracts symptoms. Planta Med. 2001;67(6):489–500.
   PubMed Web of Science ®Google Scholar
• Koch E, Biber A. Pharmakologische Wirkungen von Sabal- und Urticaextrakten als Grundlage für eine rationale medikamentöse Therapie der benignen Prostatahyperplasie. Urologe B. 1994;34(2):3–8.
   Google Scholar
• Pigat N, Reyes-Gomez E, Boutillon F, et al. Combined sabal and urtica extracts (WS® 1541) exert anti-proliferative and anti-inflammatory effects in a mouse model of benign prostate hyperplasia. Front Pharmacol. 2019;10:311.
   PubMed Web of Science ®Google Scholar
• Saponaro M, Giacomini I, Morandin G, et al. Serenoa repens and urtica dioica fixed combination: in-vitro validation of a therapy for benign prostatic hyperplasia (BPH). Int J Mol Sci. 2020;21(23):9178.
   PubMed Web of Science ®Google Scholar
• Kirschner-Hermanns R, Funk P, Leistner N. WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH. Ther Adv Urol. 2019;11:1756287219879533.
   Web of Science ®Google Scholar
• Becher H, Kostev K, Schröder-Bernhardi D. Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther. 2009;47(10):617–626.
   PubMed Web of Science ®Google Scholar
• Rathmann W, Bongaerts B, Carius HJ, et al. Basic characteristics and representativeness of the German disease analyzer database. Int J Clin Pharmacol Ther. 2018;56(10):459–466.
   PubMed Web of Science ®Google Scholar
• Eisen C, Lulic Z, Palacios-Moreno JM, et al. Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany. Int J Clin Pharmacol Ther. 2020;58(1):37–49.
   PubMed Web of Science ®Google Scholar
• Cai T, Cui Y, Yu S, et al. Comparison of Serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia: a systematic review and meta-analysis. Am J Mens Health. 2020;14(2):1557988320905407.
   Web of Science ®Google Scholar